First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung cancer (NSCLC) in a nonrandomized phase 1-2 study.
METHODS: In a randomized phase 3 trial, we evaluated the efficacy and safety of first-line selpercatinib as compared with control treatment that consisted of platinum-based chemotherapy with or without pembrolizumab at the investigator's discretion. The primary end point was progression-free survival assessed by blinded independent central review in both the intention-to-treat-pembrolizumab population (i.e., patients whose physicians had planned to treat them with pembrolizumab in the event that they were assigned to the control group) and the overall intention-to-treat population. Crossover from the control group to the selpercatinib group was allowed if disease progression as assessed by blinded independent central review occurred during receipt of control treatment.
RESULTS: In total, 212 patients underwent randomization in the intention-to-treat-pembrolizumab population. At the time of the preplanned interim efficacy analysis, median progression-free survival was 24.8 months (95% confidence interval [CI], 16.9 to not estimable) with selpercatinib and 11.2 months (95% CI, 8.8 to 16.8) with control treatment (hazard ratio for progression or death, 0.46; 95% CI, 0.31 to 0.70; P<0.001). The percentage of patients with an objective response was 84% (95% CI, 76 to 90) with selpercatinib and 65% (95% CI, 54 to 75) with control treatment. The cause-specific hazard ratio for the time to progression affecting the central nervous system was 0.28 (95% CI, 0.12 to 0.68). Efficacy results in the overall intention-to-treat population (261 patients) were similar to those in the intention-to-treat-pembrolizumab population. The adverse events that occurred with selpercatinib and control treatment were consistent with those previously reported.
CONCLUSIONS: Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, NCT04194944.).
| Errataetall: |
CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:389 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 389(2023), 20 vom: 16. Nov., Seite 1839-1850 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Caicun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 30.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT04194944 CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2309457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363632794 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363632794 | ||
| 003 | DE-627 | ||
| 005 | 20240331000720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2309457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM363632794 | ||
| 035 | |a (NLM)37870973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Caicun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04194944 | ||
| 500 | |a CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung cancer (NSCLC) in a nonrandomized phase 1-2 study | ||
| 520 | |a METHODS: In a randomized phase 3 trial, we evaluated the efficacy and safety of first-line selpercatinib as compared with control treatment that consisted of platinum-based chemotherapy with or without pembrolizumab at the investigator's discretion. The primary end point was progression-free survival assessed by blinded independent central review in both the intention-to-treat-pembrolizumab population (i.e., patients whose physicians had planned to treat them with pembrolizumab in the event that they were assigned to the control group) and the overall intention-to-treat population. Crossover from the control group to the selpercatinib group was allowed if disease progression as assessed by blinded independent central review occurred during receipt of control treatment | ||
| 520 | |a RESULTS: In total, 212 patients underwent randomization in the intention-to-treat-pembrolizumab population. At the time of the preplanned interim efficacy analysis, median progression-free survival was 24.8 months (95% confidence interval [CI], 16.9 to not estimable) with selpercatinib and 11.2 months (95% CI, 8.8 to 16.8) with control treatment (hazard ratio for progression or death, 0.46; 95% CI, 0.31 to 0.70; P<0.001). The percentage of patients with an objective response was 84% (95% CI, 76 to 90) with selpercatinib and 65% (95% CI, 54 to 75) with control treatment. The cause-specific hazard ratio for the time to progression affecting the central nervous system was 0.28 (95% CI, 0.12 to 0.68). Efficacy results in the overall intention-to-treat population (261 patients) were similar to those in the intention-to-treat-pembrolizumab population. The adverse events that occurred with selpercatinib and control treatment were consistent with those previously reported | ||
| 520 | |a CONCLUSIONS: Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, NCT04194944.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a RET protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a selpercatinib |2 NLM | |
| 650 | 7 | |a CEGM9YBNGD |2 NLM | |
| 700 | 1 | |a Solomon, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Loong, Herbert H |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Keunchil |e verfasserin |4 aut | |
| 700 | 1 | |a Pérol, Maurice |e verfasserin |4 aut | |
| 700 | 1 | |a Arriola, Edurne |e verfasserin |4 aut | |
| 700 | 1 | |a Novello, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Baohui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianying |e verfasserin |4 aut | |
| 700 | 1 | |a Ardizzoni, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mak, M Perez |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Fernando C |e verfasserin |4 aut | |
| 700 | 1 | |a Elamin, Yasir Y |e verfasserin |4 aut | |
| 700 | 1 | |a Drilon, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Payakachat, Nalin |e verfasserin |4 aut | |
| 700 | 1 | |a Uh, Minji K |e verfasserin |4 aut | |
| 700 | 1 | |a Rajakumar, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Hongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Puri, Tarun |e verfasserin |4 aut | |
| 700 | 1 | |a Soldatenkova, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, A Bence |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Boris K |e verfasserin |4 aut | |
| 700 | 1 | |a Goto, Koichi |e verfasserin |4 aut | |
| 700 | 0 | |a LIBRETTO-431 Trial Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalyszyn, Ruben |e investigator |4 oth | |
| 700 | 1 | |a Lerzo, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Paz, Gladys |e investigator |4 oth | |
| 700 | 1 | |a Martin, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Solomon, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Boyer, Michael |e investigator |4 oth | |
| 700 | 1 | |a Ganju, Vinod |e investigator |4 oth | |
| 700 | 1 | |a Mallesara, Girish |e investigator |4 oth | |
| 700 | 1 | |a Alamgeer, Muhammad |e investigator |4 oth | |
| 700 | 1 | |a Wong, Mark |e investigator |4 oth | |
| 700 | 1 | |a Lambrechts, Marc |e investigator |4 oth | |
| 700 | 1 | |a Dooms, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Surmont, Veerle |e investigator |4 oth | |
| 700 | 1 | |a Deschepper, Koenraad |e investigator |4 oth | |
| 700 | 1 | |a Goeminne, Jean-Charles |e investigator |4 oth | |
| 700 | 1 | |a Demedts, Ingel |e investigator |4 oth | |
| 700 | 1 | |a Lima, Luiz |e investigator |4 oth | |
| 700 | 1 | |a de Castro Junior, Gilberto |e investigator |4 oth | |
| 700 | 1 | |a Mak, Milena |e investigator |4 oth | |
| 700 | 1 | |a Liutti, Vitor |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Gustavo Dix |e investigator |4 oth | |
| 700 | 1 | |a Padoan, Monica |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Soares, Andrey |e investigator |4 oth | |
| 700 | 1 | |a Reis, Tercia |e investigator |4 oth | |
| 700 | 1 | |a Leighl, Natasha |e investigator |4 oth | |
| 700 | 1 | |a Chu, Quincy |e investigator |4 oth | |
| 700 | 1 | |a Han, Baohui |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Jianying |e investigator |4 oth | |
| 700 | 1 | |a Yang, Nong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Weidong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Yan |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Caicun |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ziping |e investigator |4 oth | |
| 700 | 1 | |a Yang, Mingxia |e investigator |4 oth | |
| 700 | 1 | |a Yu, Yan |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Ying |e investigator |4 oth | |
| 700 | 1 | |a Fan, Yun |e investigator |4 oth | |
| 700 | 1 | |a Dong, Xiaorong |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Chengzhi |e investigator |4 oth | |
| 700 | 1 | |a Tang, Kejing |e investigator |4 oth | |
| 700 | 1 | |a Opalka, Petr |e investigator |4 oth | |
| 700 | 1 | |a Melichar, Bohuslav |e investigator |4 oth | |
| 700 | 1 | |a Roubec, Jaromir |e investigator |4 oth | |
| 700 | 1 | |a Perol, Maurice |e investigator |4 oth | |
| 700 | 1 | |a Moro-Sibilot, Denis |e investigator |4 oth | |
| 700 | 1 | |a Quantin, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Wislez, Marie |e investigator |4 oth | |
| 700 | 1 | |a Rieke, Damian Tobias |e investigator |4 oth | |
| 700 | 1 | |a Wolf, Juergen |e investigator |4 oth | |
| 700 | 1 | |a Bischoff, Helge |e investigator |4 oth | |
| 700 | 1 | |a Reck, Martin |e investigator |4 oth | |
| 700 | 1 | |a Reinmuth, Niels |e investigator |4 oth | |
| 700 | 1 | |a Hoffknecht, Petra |e investigator |4 oth | |
| 700 | 1 | |a Schumann, Christian |e investigator |4 oth | |
| 700 | 1 | |a Mavroudis, Dimitrios |e investigator |4 oth | |
| 700 | 1 | |a Syrigos, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Baka, Sofia |e investigator |4 oth | |
| 700 | 1 | |a Kontakiotis, Theodoros |e investigator |4 oth | |
| 700 | 1 | |a Loong, Herbert |e investigator |4 oth | |
| 700 | 1 | |a Li, Yu Chung |e investigator |4 oth | |
| 700 | 1 | |a Nechushtan, Hovav |e investigator |4 oth | |
| 700 | 1 | |a Dudnik, Julia |e investigator |4 oth | |
| 700 | 1 | |a Bar, Jair |e investigator |4 oth | |
| 700 | 1 | |a Zer, Alona |e investigator |4 oth | |
| 700 | 1 | |a Peled, Nir |e investigator |4 oth | |
| 700 | 1 | |a Siena, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Bria, Emilio |e investigator |4 oth | |
| 700 | 1 | |a D'Arcangelo, Manolo |e investigator |4 oth | |
| 700 | 1 | |a Cortinovis, Diego |e investigator |4 oth | |
| 700 | 1 | |a De Carlo, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Migliorino, Maria Rita |e investigator |4 oth | |
| 700 | 1 | |a Morabito, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Novello, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Toschi, Luca |e investigator |4 oth | |
| 700 | 1 | |a Ardizzoni, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Cappuzzo, Federico |e investigator |4 oth | |
| 700 | 1 | |a Kenmotsu, Hirotsugu |e investigator |4 oth | |
| 700 | 1 | |a Kato, Terufumi |e investigator |4 oth | |
| 700 | 1 | |a Sakamoto, Tomohiro |e investigator |4 oth | |
| 700 | 1 | |a Sakakibara, Jun |e investigator |4 oth | |
| 700 | 1 | |a Kumagai, Toru |e investigator |4 oth | |
| 700 | 1 | |a Hayashi, Hidetoshi |e investigator |4 oth | |
| 700 | 1 | |a Yanagitani, Noriko |e investigator |4 oth | |
| 700 | 1 | |a Goto, Koichi |e investigator |4 oth | |
| 700 | 1 | |a Ohashi, Kadoaki |e investigator |4 oth | |
| 700 | 1 | |a Takeuchi, Shinji |e investigator |4 oth | |
| 700 | 1 | |a Ohe, Yuichiro |e investigator |4 oth | |
| 700 | 1 | |a de la Mora Jimenez, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Alatorre Alexander, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Dingemans, Anne Marie C |e investigator |4 oth | |
| 700 | 1 | |a Hashemi, Sayed |e investigator |4 oth | |
| 700 | 1 | |a Biesma, Bonne |e investigator |4 oth | |
| 700 | 1 | |a Dziadziuszko, Rafal |e investigator |4 oth | |
| 700 | 1 | |a Mazilu, Laura |e investigator |4 oth | |
| 700 | 1 | |a Alexandru, Aurelia |e investigator |4 oth | |
| 700 | 1 | |a Ciuleanu, Tudor |e investigator |4 oth | |
| 700 | 1 | |a Tiut, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Levchenko, Evgeny |e investigator |4 oth | |
| 700 | 1 | |a Moiseenko, Fedor |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 389(2023), 20 vom: 16. Nov., Seite 1839-1850 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:389 |g year:2023 |g number:20 |g day:16 |g month:11 |g pages:1839-1850 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2309457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 389 |j 2023 |e 20 |b 16 |c 11 |h 1839-1850 | ||